Last Updated: 19 Sep 2024
Executive Summary
Iteos Therapeutics Inc. (ITOS) is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapies. The company has a promising pipeline of candidates, including EOS-448, a potential first-in-class anti-TIGIT antibody, and EOS-850, a novel anti-CD3 antibody. Iteos has a strong financial position with a market capitalization of $423 million and a cash runway into 2025. The stock is currently trading at $11.59, below its analyst target price of $37.
Company Overview
Iteos Therapeutics was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company's mission is to develop innovative therapies that improve the lives of cancer patients. Iteos has a team of experienced scientists and executives with a proven track record in drug development.
Fundamental Analysis
Revenue: Iteos reported revenue of $35 million for the trailing twelve months (TTM), a 1% decline year-over-year.
Earnings: The company reported a net loss of $139 million for the TTM, resulting in an EPS of -$2.96.
Profitability: Iteos has negative profit margins, indicating that it is still in the investment phase.
Balance Sheet: The company has a strong balance sheet with $268 million in cash and equivalents.
Pipeline: Iteos has a promising pipeline of candidates, including EOS-448 and EOS-850.
Technical Analysis
Price Action: ITOS has been trading in a range between $8.20 and $18.75 over the past 52 weeks.
Moving Averages: The stock is currently trading below its 50-day and 200-day moving averages.
Support and Resistance: There is support at $10 and resistance at $13.
Short Term Outlook
In the short term, ITOS is likely to remain range-bound. The stock is facing resistance at $13 and support at $10. A break above $13 could lead to a rally towards the analyst target price of $37. However, a break below $10 could lead to a decline towards $8.20.
Long Term Outlook
In the long term, ITOS has the potential to be a successful company. The company has a promising pipeline of candidates and a strong financial position. If Iteos is able to successfully develop and commercialize its therapies, the stock could appreciate significantly.
Analyst Recommendations
Analysts are bullish on ITOS, with 2 strong buy ratings and 4 buy ratings. The average analyst target price is $37, which represents a potential upside of over 200% from the current price.
